JO
CLDX icon

John Overdeck’s Celldex Therapeutics CLDX Stock Holding History

John Overdeck’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6M Buy
661,235
+524,220
+383% +$16.9M 0.02% 922
2026
Q1 		$4.35M Buy
137,015
+4,482
+3% +$122K ﹤0.01% 2091
2025
Q4 		$3.6M Buy
132,533
+59,132
+81% +$1.56M 0.01% 2001
2025
Q3 		$1.9M Sell
73,401
-7,332
-9% -$170K ﹤0.01% 2164
2025
Q2 		$1.64M Buy
80,733
+52,077
+182% +$1.01M ﹤0.01% 1960
2025
Q1 		$520K Sell
28,656
-4,369
-13% -$97.6K ﹤0.01% 2505
2024
Q4 		$835K Buy
+33,025
New +$897K ﹤0.01% 2290
2024
Q2 		– Sell
-151,391
Closed -$6.35M – 3068
2024
Q1 		$6.35M Buy
+151,391
New +$6.22M 0.01% 849
2023
Q3 		– Sell
-18,423
Closed -$625K – 2977
2023
Q2 		$625K Sell
18,423
-6,661
-27% -$224K ﹤0.01% 2222
2023
Q1 		$903K Buy
+25,084
New +$1.08M ﹤0.01% 1929
2022
Q4 		– Sell
-29,780
Closed -$837K – 2827
2022
Q3 		$837K Sell
29,780
-243,840
-89% -$7.48M ﹤0.01% 1546
2022
Q2 		$7.38M Buy
273,620
+44,672
+20% +$1.3M 0.02% 614
2022
Q1 		$7.8M Buy
228,948
+35,307
+18% +$1.13M 0.02% 705
2021
Q4 		$7.48M Buy
+193,641
New +$8.44M 0.02% 959
2021
Q1 		– Sell
-196,792
Closed -$3.45M – 3863
2020
Q4 		$3.45M Sell
196,792
-193,150
-50% -$3.48M 0.01% 1142
2020
Q3 		$5.78M Buy
389,942
+258,848
+197% +$3.03M 0.02% 737
2020
Q2 		$1.7M Buy
+131,094
New +$581K 0.01% 1182
2019
Q3 		– Sell
-34,308
Closed -$92K – 3489
2019
Q2 		$92K Buy
+34,308
New +$117K ﹤0.01% 3211
2019
Q1 		– Sell
-116,072
Closed -$345K – 3069
2018
Q4 		$345K Buy
116,072
+1,724
+2% +$8.47K ﹤0.01% 2362
2018
Q3 		$774K Buy
114,348
+24,241
+27% +$170K ﹤0.01% 2162
2018
Q2 		$681K Buy
+90,107
New +$1.2M ﹤0.01% 2431
2018
Q1 		– Sell
-18,791
Closed -$800K – 3187
2017
Q4 		$800K Buy
+18,791
New +$805K ﹤0.01% 2116

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's CLDX Position: Q2 2026 in Review

John Overdeck increased its Celldex Therapeutics (CLDX) stake by 383% in Q2 2026, buying an estimated $16.9M and bringing the position to 661,235 shares worth $24.6M. The position accounts for 0.02% of the portfolio, ranked #922.

John Overdeck first reported a position in CLDX in Q4 2017 and has held it in 22 quarters since. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • John Overdeck held 661,235 shares of Celldex Therapeutics worth $24.6M as of Q2 2026.
  • John Overdeck bought 524,220 Celldex Therapeutics shares in Q2 2026, an estimated $16.9M.
  • Celldex Therapeutics made up 0.02% of John Overdeck's portfolio in Q2 2026, its #922 holding.
  • John Overdeck first reported a position in Celldex Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.